Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 08  •  04:00PM ET
52.95
Dollar change
0.00
Percentage change
0.00
%
Index
RUT
P/E
30.05
EPS (ttm)
1.76
Insider Own
4.05%
Shs Outstand
51.72M
Perf Week
0.15%
Market Cap
2.76B
Forward P/E
8.42
EPS next Y
6.29
Insider Trans
-0.66%
Shs Float
50.01M
Perf Month
0.84%
Enterprise Value
2.56B
PEG
0.05
EPS next Q
0.68
Inst Own
96.46%
Perf Quarter
27.50%
Income
95.62M
P/S
9.68
EPS this Y
912.39%
Inst Trans
-8.43%
Perf Half Y
12.97%
Sales
285.01M
P/B
5.52
EPS next Y
59.18%
ROA
20.64%
Perf YTD
14.36%
Book/sh
9.59
P/C
10.80
EPS next 5Y
181.21%
ROE
26.27%
52W High
90.32 -41.38%
Perf Year
-30.57%
Cash/sh
4.90
P/FCF
26.18
EPS past 3/5Y
- -
ROIC
17.42%
52W Low
29.43 79.92%
Perf 3Y
1160.71%
Dividend Est.
-
EV/EBITDA
27.95
Sales past 3/5Y
- -
Gross Margin
98.63%
Volatility
0.09% 0.20%
Perf 5Y
218.02%
Dividend TTM
-
EV/Sales
8.98
EPS Y/Y TTM
139.08%
Oper. Margin
31.40%
ATR (14)
0.63
Perf 10Y
-39.14%
Dividend Ex-Date
-
Quick Ratio
5.32
Sales Y/Y TTM
-
Profit Margin
33.55%
RSI (14)
77.55
Dividend Gr. 3/5Y
- -
Current Ratio
5.62
EPS Q/Q
162.38%
SMA20
0.33%
Beta
-2.23
Payout
0.00%
Debt/Eq
0.11
Sales Q/Q
-
SMA50
20.13%
Rel Volume
0.36
Prev Close
52.95
Employees
182
LT Debt/Eq
0.11
SMA200
-0.81%
Avg Volume
3.36M
Price
52.95
IPO
Nov 13, 2014
Option/Short
Yes / Yes
Trades
Volume
1,198,191
Change
0.00%
Date Action Analyst Rating Change Price Target Change
Nov-18-25Initiated Wolfe Research Outperform $75
Oct-07-25Initiated Goldman Buy $125
Aug-20-25Initiated Wells Fargo Overweight $123
Jun-23-25Initiated TD Cowen Buy $110
Mar-05-25Resumed Stifel Buy $74
Dec-02-24Reiterated Stifel Buy $74
Dec-02-24Reiterated Robert W. Baird Outperform $72
Sep-03-24Initiated H.C. Wainwright Buy $70
May-10-24Initiated Robert W. Baird Outperform $72
Feb-05-24Initiated Piper Sandler Overweight $93
May-08-26 05:57PM
May-06-26 08:30AM
Apr-23-26 11:43AM
Apr-20-26 04:31PM
Apr-15-26 07:59AM
08:01PM Loading…
Apr-11-26 08:01PM
Apr-10-26 02:30PM
Apr-07-26 09:47AM
Apr-06-26 05:30PM
04:06PM
03:28PM
10:30AM
09:35AM
08:58AM
07:34AM
07:24AM Loading…
07:24AM
07:18AM
07:12AM
07:04AM
07:00AM
05:56AM
Apr-01-26 03:43PM
Mar-16-26 03:03AM
Mar-12-26 09:00AM
04:40AM
Mar-10-26 08:00AM
Mar-09-26 08:31PM
Mar-04-26 02:30AM
Mar-01-26 04:27AM
Feb-26-26 12:33PM
08:00AM Loading…
08:00AM
03:08AM
12:04AM
Feb-25-26 04:01PM
Feb-19-26 12:42PM
Feb-16-26 12:24PM
Feb-15-26 06:39AM
Feb-11-26 08:00AM
Feb-02-26 11:03AM
09:35AM
Jan-30-26 10:24AM
Jan-29-26 08:00AM
Jan-27-26 12:59PM
07:22AM
Jan-23-26 04:56AM
Jan-22-26 10:21PM
Jan-14-26 09:55AM
Jan-13-26 04:28AM
Jan-12-26 07:00AM
Jan-09-26 03:16AM
Jan-08-26 09:36AM
Jan-07-26 08:45AM
Jan-06-26 08:00AM
Jan-05-26 08:00AM
Dec-11-25 04:27PM
Dec-10-25 10:32AM
Dec-03-25 04:05PM
Nov-30-25 12:26AM
Nov-25-25 08:39AM
Nov-24-25 08:00AM
Nov-21-25 05:22AM
Nov-11-25 07:00AM
Nov-07-25 10:04AM
Nov-06-25 12:07PM
Nov-05-25 06:26AM
12:03AM
Nov-04-25 04:01PM
Nov-03-25 07:28AM
Oct-28-25 08:00AM
Oct-22-25 05:01PM
Oct-21-25 08:00AM
Oct-17-25 09:54PM
Oct-13-25 08:00AM
Oct-07-25 01:05PM
Sep-30-25 04:01AM
Sep-25-25 10:50AM
10:23AM
Sep-24-25 04:20PM
07:28AM
Sep-18-25 10:38AM
Sep-12-25 06:45AM
Sep-11-25 09:35AM
02:18AM
Sep-10-25 12:59AM
Aug-27-25 08:00AM
Aug-20-25 04:02PM
09:34AM
Aug-19-25 09:35AM
Aug-15-25 09:57AM
Aug-11-25 09:55AM
08:50AM
Aug-06-25 05:10PM
04:01PM
Jul-28-25 08:00AM
Jul-25-25 12:00PM
Jul-23-25 09:55AM
08:50AM
Jul-21-25 12:15AM
Jul-10-25 09:59AM
09:07AM
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning MeredithChief Commercial OfficerMar 27 '26Sale30.447,522228,98064,507Mar 31 08:17 PM
Huang Michael F.Sr. VP of Clinical DevelopmentMar 27 '26Sale30.446,582200,36539,823Mar 31 08:15 PM
Abingworth Bioventures VII LPShareholderAug 11 '25Proposed Sale82.151,347,522110,696,581Aug 15 09:00 PM
Hirano Patricia CSEE REMARKSJul 01 '25Sale82.763,830316,97113,206Jul 03 04:41 PM
PATRICIA HIRANOOfficerJul 01 '25Proposed Sale82.763,830316,971Jul 01 04:03 PM
Hirano Patricia CSEE REMARKSJun 24 '25Option Exercise44.2526611,77017,302Jun 26 06:04 PM
Hirano Patricia CSEE REMARKSJun 24 '25Sale84.2526622,41017,036Jun 26 06:04 PM
PATRICIA HIRANOOfficerJun 24 '25Proposed Sale84.2526622,410Jun 24 04:07 PM